Marseille, France, September 18, 2012 - Trophos SA, a French pharmaceutical company developing innovative therapies in neurology and cardiology up to the clinical validation stage, announces today the appointment of Marceline Clementine as chief financial officer.
Marceline Clementine has more than 30 years experience in the world of finance. She joined Trophos in 2006 as administration and finance manager. Before that, she had worked as chief accountant or financial controller at various companies in the real estate and catering sectors, including Groupe FLO.
She is now responsible for all administrative and financial services at Trophos, as well as for human resources management. Marceline Clementine succeeds Christine Placet, the former chief financial officer, who has just been promoted to the post of chief executive officer of Trophos.
“We are delighted to welcome Marceline Clementine as chief financial officer,” said Christine Placet, the CEO of Trophos. “This appointment is a recognition of Ms. Clementine’s competence in financial matters and her strong commitment to Trophos over the past few years. Her financial management skills are a precious asset for the company. We are continuing our quest to find strategic partners for our current programs to guarantee the future of our company, which was founded 13 years ago now.”
Trophos has sufficient funding in hand to continue its research activities up to 2014. The company is currently undertaking several programs focused on the following drug candidates:
• Olesoxime in Spinal Muscular Atrophy (SMA): a pivotal study is underway and the results are expected in the second half of 2013.
• Olesoxime for multiple sclerosis (MS) disease progression: a phase II proof-of-concept study has been designed in conjunction with international MS specialists.
• TRO40303 cardiac protection compound: a phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI) is underway and the results are expected in the first half of 2013.
About Trophos SA – http://www.trophos.com
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in a pivotal clinical study for Spinal Muscular Atrophy (substantially funded by the AFM patient association). Olesoxime is also ready for a phase II proof of concept study in Multiple Sclerosis (MS) disease progression. A second product, TRO40303, is in phase II clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare). Trophos' mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs, which Trophos is uniquely placed to exploit.
Trophos, founded in 1999, is based in Marseille, France and currently has 27 employees.
ANDREW LLOYD & ASSOCIATES
Follow us on Twitter: https://twitter.com/ALA_Group
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION